J&J’s Tecvayli/Darzalex nod is the second under a new priority voucher scheme.
ApexOnco Front Page
Recent articles
Rinzimetostat efficacy wanes further as the company moves into phase 3.
Though lung cancer looks promising a partner is now needed.
Deteriorating efficacy and a treatment-related death with Zynlonta plus Columvi spook investors.
The company’s AN9025 will shortly enter phase 1.
With a phase 3 trial of the trispecific T-cell engager ramantamig, J&J will challenge itself.
The upcoming Rasolute-304 trial will compare daraxonrasib versus observation.
A more comprehensive dataset on JANX007 sends the group’s stock down.
